Integra LifeSciences (IART) to Release Earnings on Thursday

Integra LifeSciences (NASDAQ:IART) is expected to be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Integra LifeSciences to post earnings of $0.80 per share and revenue of $429.62 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $11.99 on Thursday. The business’s fifty day simple moving average is $12.18 and its 200-day simple moving average is $13.25. The company has a quick ratio of 1.80, a current ratio of 3.14 and a debt-to-equity ratio of 1.73. The firm has a market cap of $933.90 million, a PE ratio of -1.86 and a beta of 1.04. Integra LifeSciences has a 52 week low of $10.60 and a 52 week high of $25.45.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IART. Citigroup reduced their price target on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating on the stock in a research note on Friday, October 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Monday, December 29th. Wall Street Zen raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Truist Financial reiterated a “hold” rating and issued a $13.00 price objective (down previously from $15.00) on shares of Integra LifeSciences in a report on Monday, November 3rd. Finally, JPMorgan Chase & Co. raised their target price on Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a report on Friday, October 31st. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $15.00.

Institutional Trading of Integra LifeSciences

A number of large investors have recently made changes to their positions in the company. Rubric Capital Management LP lifted its stake in Integra LifeSciences by 1.3% in the fourth quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock worth $96,304,000 after acquiring an additional 100,000 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Integra LifeSciences by 9.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after purchasing an additional 267,134 shares in the last quarter. State Street Corp raised its holdings in shares of Integra LifeSciences by 0.8% in the 4th quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock valued at $34,933,000 after purchasing an additional 21,717 shares in the last quarter. Paradigm Capital Management Inc. NY increased its holdings in Integra LifeSciences by 5.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company’s stock valued at $33,099,000 after buying an additional 135,198 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Integra LifeSciences by 8.8% in the fourth quarter. Geode Capital Management LLC now owns 1,683,964 shares of the life sciences company’s stock valued at $20,918,000 after buying an additional 135,743 shares during the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.